PMID: 41890775
Insights into Tanning Biology and Tanning Products.
Resnick Gabriella, Khajeh-Afzaly Megan, Yousefian Faraz et al.
The Journal of clinical and aesthetic dermatology · 2026
Research Library
Melanotan I
19 papers indexed
PMID: 40584950
A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic in a tertiary referral centre.
Lai Fei Ya, Quigley Claire, Murray Gregg et al.
Skin health and disease · 2025
PMID: 39296259
Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs).
Weirath Nicholas A, Haskell-Luevano Carrie
ACS pharmacology & translational science · 2025
PMID: 38035762
Effects of the central melanocortin system on feed intake, metabolic hormones and insulin action in the sheep.
Ehrhardt Richard A, Giesy Sarah L, Hileman Stanley M et al.
Journal of animal science · 2023
PMID: 30142729
A glimpse into the underground market of melanotan.
Callaghan Iii Daniel J
Dermatology online journal · 2018
PMID: 28266027
Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.
Habbema Louis, Halk Anne Berthe, Neumann Martino et al.
International journal of dermatology · 2018
PMID: 26806443
The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review.
Brennan Rebekah, Wells John S G, Van Hout Marie Claire
Health & social care in the community · 2018
PMID: 26315100
[Undesirable pigmentation].
Bayerl C
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2016
PMID: 25096243
Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.
Ückert Stefan, Bannowsky Andreas, Albrecht Knut et al.
Expert opinion on investigational drugs · 2015
PMID: 23121206
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.
Nelson Michael E, Bryant Sean M, Aks Steven E
Clinical toxicology (Philadelphia, Pa.) · 2013
PMID: 20545686
Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?
Langan E A, Nie Z, Rhodes L E
The British journal of dermatology · 2011
PMID: 19224885
Use of melanotan I and II in the general population.
Evans-Brown Michael, Dawson Rob T, Chandler Martin et al.
BMJ (Clinical research ed.) · 2009
PMID: 17344945
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous J R
Methods and findings in experimental and clinical pharmacology · 2007
PMID: 16412534
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.
Hadley Mac E, Dorr Robert T
Peptides · 2006
PMID: 11045725
Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.
Dorr R T, Dvorakova K, Brooks C et al.
Photochemistry and photobiology · 2000
PMID: 10888312
Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.
Bhardwaj R, Hadley M E, Dorr R T et al.
Pharmaceutical research · 2000
PMID: 9760697
Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
Hadley M E, Hruby V J, Blanchard J et al.
Pharmaceutical biotechnology · 1998
PMID: 8877878
Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407.
Bhardwaj R, Blanchard J
Journal of pharmaceutical sciences · 1997
PMID: 9113347
Skin pigmentation and pharmacokinetics of melanotan-I in humans.
Ugwu S O, Blanchard J, Dorr R T et al.
Biopharmaceutics & drug disposition · 1997
For research use only. This index links to third-party literature. Nothing here constitutes medical advice.